



*SA*

PATENT  
Attorney Docket 056707-5001-01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Gregory M. Glenn <i>et al.</i></b>	)	Confirmation No. <b>4303</b>
	)	
Application No. <b>10/790,715</b>	)	Group Art Unit: <b>1644</b>
	)	
Filed: <b>March 3, 2004</b>	)	Examiner: <b>Yunsoo Kim</b>
	)	
For: <b>Use of Penetration Enhancers and Barrier</b>	)	Date: <b>June 5, 2007</b>
<b>Disruption Methods to Enhance the</b>	)	
<b>Immune Response of Antigen and</b>	)	
<b>Adjuvant (as amended)</b>	)	


U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

**TRANSMITTAL FORM**

1. Transmitted herewith Request for Corrected Filing Receipt.
2. Additional Papers Submitted:
  - (i) Marked-up copy of filing receipt
  - (ii) Copy of as-filed Declaration/Power of Attorney
3. Constructive Petition: **Except** for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **June 5, 2007**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
Sally P. Teng, Ph.D.  
Registration No. 45,397



PATENT  
Attorney Docket 056707-5001-01

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Gregory M. Glenn <i>et al.</i></b>	)	Confirmation No. <b>4303</b>
	)	
Application No. <b>10/790,715</b>	)	Group Art Unit: <b>1644</b>
	)	
Filed: <b>March 3, 2004</b>	)	Examiner: <b>Yunsoo Kim</b>
	)	
For: <b>Use of Penetration Enhancers and Barrier</b>	)	Date: <b>June 5, 2007</b>
<b>Disruption Methods to Enhance the</b>	)	
<b>Immune Response of Antigen and</b>	)	
<b>Adjuvant (as amended)</b>	)	

**REQUEST FOR CORRECTED FILING RECEIPT**

Attached is a copy of the Official Filing Receipt received from the U.S. Patent Office in the above-referenced application for which issuance of a corrected filing receipt is respectfully requested as there is an error with respect to the Domestic Priority Data.

The present application is a continuation application of U.S. Application No. 09/257,188, filed February 25, 1999, now U.S. Patent 6,797,276, which is a continuation-in-part of U.S. Application No. 08/749,164, filed November 14, 1996, now U.S. Patent No. 5,910,306; U.S. Application No. 08/896,085, filed July 17, 1997, now U.S. Patent No. 5,980,898; and PCT/US97/21324 designating the U.S., filed November 14, 1997, now abandoned, published under PCT Article 21(2) in English. U.S. Application No. 09/257,188 claims the benefit of U.S. Provisional Application No. 60/075,850, filed February 25, 1998; U.S. Provisional Application No. 60/075,856, filed February 25, 1998; and U.S. Provisional Application No. 60/086,251, filed May 21, 1998.

Domestic Priority Data: Please correct the Domestic Priority Data as follows:

This application is a CON of 09/257,188 02/25/1999 PAT 6,797,276  
which is a CIP of 08/749,164 11/14/1996 PAT 5,910,306  
and also a CIP of 08/896,085 07/17/1997 PAT 5,980,898  
and also a CIP of PCT/US97/21324 11/14/1997 abandoned

This application is a CON of 09/257,188 which claims the benefit of  
U.S. Provisional Application 60/075,850 02/25/1998


U.S. Provisional Application 60/075,856 02/25/1998

U.S. Provisional Application 60/086,251 05/21/1998

If there are any fees due in connection with the filing of this Request, please charge the fees to our Deposit Account No. 50-310. If a fee is required for an extension of time under 37 C.F.R. 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **June 5, 2007**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
Sally P. Teng  
Registration No. 45,397



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/790,715	03/03/2004	1645	770	056707-5001-01	5	11	1

CONFIRMATION NO. 4303

009629

MORGAN LEWIS & BOCKIUS LLP  
1111 PENNSYLVANIA AVENUE NW  
WASHINGTON, DC 20004

## FILING RECEIPT



\*OC000000012511902\*

Date Mailed: 05/03/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Gregory M. Glenn, Cabin John, MD;  
Carl R. Alving, Bethesda, MD;

## Assignment For Published Patent Application

Government of the United States, as Represented by the Secretary of the Army;

## Domestic Priority data as claimed by applicant

This application is a CON of 09/257,188 02/25/1999  
which is a CIP of 08/749,164 11/14/1996 PAT 5,910,306

This application is a CON of 09/257,188 02/25/1999 PAT 6,797,276

which is a CIP of 08/749,164 11/14/1996 PAT 5,910,306

and also a CIP of 08/896,085 07/17/1997 PAT 5,980,898

and also a CIP of PCT/US97/21324 11/14/1997 abandoned.

## Foreign Applications

This application is a CON of 09/257,188 which claims the benefit of

U.S. Provisional Application 60/075,850 02/25/1998

U.S. Provisional Application 60/075,856 02/25/1998

U.S. Provisional Application 60/086,251 05/21/1998

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

RECEIVED

MAY 17 2004

MORGAN, LEWIS &amp; BOCKIUS LLP

Title

56707-5001-01  
DOCKETED  
By DLW Date 5/17/04

Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin



---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FOR UTILITY/DESIGN  
CIP/PCT NATIONAL/PLANT  
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL  
DECLARATIONS



RULE 63 (37 C.F.R. 1.56)  
DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION

PW  
FORM

THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED Use of Penetration Enhancers and Barrier Disruption Agents to Enhance the Transcutaneous Immune Response Induced by ADP-Ribosylating Exotoxin

the specification of which (CHECK applicable BOX(ES))  
X A. ☐ is attached hereto.  
BOX(ES) → B. ☒ was filed on February 25, 1999 as U.S. Application No. 09/257,188  
→ C. ☐ was filed as PCT International Application No. PCT/ / on /  
and (if applicable to U.S. or PCT application) was amended on /

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

**PRIOR FOREIGN APPLICATION(S)**

Number	Country	Day/MONTH/Year Filed	Date first Laid-open or Published	Date Patented or Granted	Priority NOT Claimed
--------	---------	----------------------	-----------------------------------	--------------------------	----------------------

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT International applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

**PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)**

Application No. (series code/serial no.)	Day/MONTH/Year Filed	Status	Priority NOT Claimed
08/749,184	14/NOV/1996	pending, abandoned, patented	
08/896,085	17/JUL/1997	patented	
PCT/US97/21324	14/NOV/1997	patented	
60/075,850	25/FEB/1998	abandoned	
60/075,856	25/FEB/1998	abandoned	
60/086,251	21/MAY/1998	abandoned	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop LLP, Intellectual Property Group, 1600 Tysons Boulevard, McLean, VA 22102, telephone number (703) 905-2000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16773	David A. Jakopin	32995	Adam R. Hess	41835	Brian J. Beatus	38825
George M. Sirilla	18221	Mark G. Paulson	30793	William P. Atkins	38821	Jonathan E. Jobe	28429
Donald J. Bird	25323	Stephen C. Glazier	31361	Paul L. Sharer	36004	Mark C. Pickering	36239
Dale S. Lazar	28872	Richard H. Zaitlen	27248	Robin L. Teskin	35030	David H. Jaffer	32243
Glenn J. Perry	28458	Roger R. Wise	31204	Anthony L. Miele	34393	John R. Wetherell	31678
G. Paul Edgell	24238	Jack S. Barufka	37087	Robert J. Walters	40862	Steven J. Moore	35959
				Gary R. Tanigawa	43180	Elizabeth Arwine	45867

(1) INVENTOR'S SIGNATURE:

*Glenn M. A.*

Date: 14 Aug 2001

Name	Gregory	M.	GLENN
First	Middle Initial	Family Name	
Residence	Cabin John	MD	U.S.A.
City	State/Foreign Country		Country of Citizenship
Mailing Address	8010 Riverside Drive, Cabin John Maryland 20818		
(include Zip Code)			

(2) INVENTOR'S SIGNATURE:

*Carl R. Alving*

Date: 21 Aug 2001

Name	Carl	R.	ALVING
First	Middle Initial	Family Name	
Residence	Bethesda	MD	U.S.A.
City	State/Foreign Country		Country of Citizenship
Mailing Address	3 Newbold Court, Bethesda, Maryland 20817		
(include Zip Code)			

Atty. Dkt. No. PW 244954 / 1002

(M#)